Benzinga · Aug 10, 2026
B. Riley Securities Maintains Neutral on Biote, Lowers Price Target to $1.5
B. Riley Securities analyst Jeff Van Sinderen maintains Biote (NASDAQ:BTMD) with a Neutral and lowers the price target from $2 to $1.5.
NASDAQ · BTMD
biote Corp.
Healthcare · Medical - Care Facilities
$1.34
Up+$0.04 (+2.99%)
Updated Sep 17, 2026, 7:41 PM
SID Score
3.6/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 136.76M
- P/E ratio
- 3.11
- Dividend yield
- 0.00%
- 52-week range
- $1.27 – $3.52
- Volume
- 69.16K
- Avg. volume
- 121.8K
Price performance
BTMD price history
1M range · 20 trading sessions · Daily adjusted prices
BTMD closed at $1.34 after 20 trading sessions, down 1.47% for the selected period.
- Last close
- $1.34
- Period change
- -1.47%
- Period low
- $1.31
- Period high
- $1.69
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 16, 2026 | $1.43 | $1.43 | $1.3307 | $1.34 | 69.16K |
| Sep 15, 2026 | $1.40 | $1.46 | $1.38 | $1.39 | 271.02K |
| Sep 14, 2026 | $1.33 | $1.41 | $1.33 | $1.40 | 174.58K |
| Sep 11, 2026 | $1.32 | $1.40 | $1.32 | $1.33 | 138.44K |
| Sep 10, 2026 | $1.45 | $1.454 | $1.30 | $1.31 | 298.64K |
| Sep 9, 2026 | $1.51 | $1.51 | $1.44 | $1.45 | 59.46K |
| Sep 8, 2026 | $1.53 | $1.56 | $1.45 | $1.51 | 119.56K |
| Sep 4, 2026 | $1.55 | $1.60 | $1.515 | $1.545 | 77.4K |
| Sep 3, 2026 | $1.70 | $1.71 | $1.51 | $1.55 | 88.43K |
| Sep 2, 2026 | $1.67 | $1.80 | $1.63 | $1.69 | 585.14K |
| Sep 1, 2026 | $1.63 | $1.69 | $1.56 | $1.67 | 692.93K |
| Aug 31, 2026 | $1.57 | $1.6562 | $1.53 | $1.64 | 313.96K |
| Aug 28, 2026 | $1.63 | $1.69 | $1.57 | $1.57 | 141.92K |
| Aug 27, 2026 | $1.55 | $1.66 | $1.5238 | $1.63 | 708.24K |
| Aug 26, 2026 | $1.59 | $1.61 | $1.54 | $1.55 | 60.13K |
| Aug 25, 2026 | $1.57 | $1.625 | $1.52 | $1.58 | 195.26K |
| Aug 24, 2026 | $1.61 | $1.672 | $1.45 | $1.57 | 216.41K |
| Aug 21, 2026 | $1.48 | $1.615 | $1.48 | $1.61 | 275.36K |
| Aug 20, 2026 | $1.36 | $1.68 | $1.36 | $1.48 | 2.17M |
| Aug 19, 2026 | $1.33 | $1.39 | $1.33 | $1.36 | 91.43K |
Latest BTMD news
The latest Smart Investors Daily articles mentioning BTMD.
Stock researchCompany · Overview
BTMD research
Overview
Company profile and research snapshot.
Company profile
Biote Corp operates a growth practice-building business within the hormone optimization space. It provides the necessary components to enable Biote-certified practitioners to establish, build, and successfully implement a program designed to optimize hormone levels using personalized solutions for their patient populations. The company derives revenue from United States and also has its presence in other countries.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- Buy
- Average target
- $8.62
- Implied upside
- —
- Analysts
- 11
| Date | Firm | Rating | Target |
|---|---|---|---|
| Aug 10, 2026 | B. Riley Securities | Neutral | — |
| Aug 7, 2026 | TD Cowen | Buy | — |
| Apr 16, 2026 | Truist Securities | Buy | — |
| Mar 12, 2026 | TD Cowen | Buy | — |
| Mar 12, 2026 | B. Riley Securities | Neutral | — |
News briefing
No generated briefing is available yet.
Benzinga · Aug 7, 2026
TD Cowen Maintains Buy on Biote, Lowers Price Target to $2
TD Cowen analyst Jonna Kim maintains Biote (NASDAQ:BTMD) with a Buy and lowers the price target from $2.5 to $2.
Yahoo · Aug 6, 2026
Biote Corp (BTMD) (Q2 2026) Earnings Call Highlights: Navigating Recall Challenges and ...
Despite a 9.5% revenue decline and revised guidance, Biote Corp (BTMD) focuses on operational recovery, supply normalization, and inorganic growth opportunities.
SeekingAlpha · Aug 6, 2026
biote Corp. (BTMD) Q2 2026 Earnings Call Transcript
biote Corp. (BTMD) Q2 2026 Earnings Call August 5, 2026 5:00 PM EDTCompany ParticipantsRobert Peterson - Interim CEO, CFO & Chief Business...
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
